# Cellectar Biosciences, Inc.: financial statements, quarterly

CLRB · Nasdaq · CIK 1279704 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clrb.md) · [Financials](/companies/clrb/financials.md) · [Filings](/companies/clrb/filings.md) · [Insiders](/companies/clrb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clrb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [7.0](/filings/0001410578-24-002012.md) | [7.7 d](/filings/0001410578-25-000329.md) | [7.1](/filings/0001410578-25-001205.md) | [7.3](/filings/0001410578-25-001778.md) | [5.5](/filings/0001104659-25-110827.md) | [6.2 d](/filings/0001104659-26-023167.md) | [3.4](/filings/0001104659-26-060678.md) | [2.4](/filings/0001104659-26-095426.md) | [2.5](/filings/0001104659-25-110827.md) | [3.2 d](/filings/0001104659-26-023167.md) | [3.0](/filings/0001104659-26-060678.md) | [4.6](/filings/0001104659-26-095426.md) |
| Operating income | $m | [(9.4)](/filings/0001410578-24-002012.md) | [(12.5) d](/filings/0001410578-25-000329.md) | [(12.0)](/filings/0001410578-25-001205.md) | [(13.7)](/filings/0001410578-25-001778.md) | [(13.3)](/filings/0001104659-25-110827.md) | [(12.7) d](/filings/0001104659-26-023167.md) | [(6.4)](/filings/0001104659-26-060678.md) | [(6.0)](/filings/0001104659-26-095426.md) | [(4.9)](/filings/0001104659-25-110827.md) | [(5.7) d](/filings/0001104659-26-023167.md) | [(5.8)](/filings/0001104659-26-060678.md) | [(7.2)](/filings/0001104659-26-095426.md) |
| Net income | $m | [(17.5)](/filings/0001410578-24-002012.md) | [(7.9) d](/filings/0001410578-25-000329.md) | [(26.6)](/filings/0001104659-25-110827.md) | [(0.9)](/filings/0001104659-25-110827.md) | [(14.7)](/filings/0001104659-25-110827.md) | [(2.4) d](/filings/0001104659-26-023167.md) | [(6.6)](/filings/0001104659-26-095426.md) | [(5.4)](/filings/0001104659-26-095426.md) | [(4.4)](/filings/0001104659-25-110827.md) | [(5.3) d](/filings/0001104659-26-023167.md) | [(5.7)](/filings/0001104659-26-095426.md) | [(6.9)](/filings/0001104659-26-095426.md) |
| Diluted EPS | $ per share | [(1.55)](/filings/0001410578-24-002012.md) | not reported | [(0.91)](/filings/0001410578-25-001205.md) | [(5.43)](/filings/0001410578-25-001778.md) | [(12.13)](/filings/0001104659-25-110827.md) | not reported | [(4.30)](/filings/0001104659-26-060678.md) | [(3.39)](/filings/0001104659-26-095426.md) | [(1.41)](/filings/0001104659-25-110827.md) | not reported | [(1.33)](/filings/0001104659-26-060678.md) | [(0.57)](/filings/0001104659-26-095426.md) |
| Basic EPS | $ per share | [(1.55)](/filings/0001410578-24-002012.md) | not reported | [(0.91)](/filings/0001410578-25-001205.md) | [(0.77)](/filings/0001410578-25-001778.md) | [(11.18)](/filings/0001104659-25-110827.md) | not reported | [(4.30)](/filings/0001104659-26-060678.md) | [(3.39)](/filings/0001104659-26-095426.md) | [(1.41)](/filings/0001104659-25-110827.md) | not reported | [(1.33)](/filings/0001104659-26-060678.md) | [(0.57)](/filings/0001104659-26-095426.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.0](/filings/0001410578-24-001704.md) | [9.6](/filings/0001410578-25-000329.md) | [40.0](/filings/0001410578-24-001706.md) | [25.9](/filings/0001410578-24-001708.md) | [34.3](/filings/0001410578-24-002012.md) | [23.3](/filings/0001104659-26-023167.md) | [13.9](/filings/0001410578-25-001205.md) | [11.0](/filings/0001410578-25-001778.md) | [12.6](/filings/0001104659-25-110827.md) | [13.2](/filings/0001104659-26-095426.md) | [8.3](/filings/0001104659-26-060678.md) | [34.0](/filings/0001104659-26-095426.md) |
| Current assets | $m | [20.1](/filings/0001410578-24-001704.md) | [10.5](/filings/0001410578-25-000329.md) | [41.4](/filings/0001410578-24-001706.md) | [27.9](/filings/0001410578-24-001708.md) | [35.9](/filings/0001410578-24-002012.md) | [24.3](/filings/0001104659-26-023167.md) | [14.9](/filings/0001410578-25-001205.md) | [12.6](/filings/0001410578-25-001778.md) | [13.6](/filings/0001104659-25-110827.md) | [14.0](/filings/0001104659-26-095426.md) | [9.3](/filings/0001104659-26-060678.md) | [34.9](/filings/0001104659-26-095426.md) |
| Total assets | $m | [21.6](/filings/0001410578-24-001704.md) | [12.1](/filings/0001410578-25-000329.md) | [42.9](/filings/0001410578-24-001706.md) | [29.4](/filings/0001410578-24-001708.md) | [37.3](/filings/0001410578-24-002012.md) | [25.5](/filings/0001104659-26-023167.md) | [16.0](/filings/0001410578-25-001205.md) | [13.7](/filings/0001410578-25-001778.md) | [14.6](/filings/0001104659-25-110827.md) | [15.0](/filings/0001104659-26-095426.md) | [11.1](/filings/0001104659-26-060678.md) | [36.6](/filings/0001104659-26-095426.md) |
| Current liabilities | $m | [29.8](/filings/0001410578-24-001704.md) | [25.4](/filings/0001410578-25-000329.md) | [28.6](/filings/0001410578-24-001706.md) | [15.2](/filings/0001410578-24-001708.md) | [20.3](/filings/0001410578-24-002012.md) | [9.4](/filings/0001104659-26-023167.md) | [6.0](/filings/0001410578-25-001205.md) | [5.9](/filings/0001410578-25-001778.md) | [4.9](/filings/0001104659-25-110827.md) | [4.7](/filings/0001104659-26-095426.md) | [4.9](/filings/0001104659-26-060678.md) | [5.2](/filings/0001104659-26-095426.md) |
| Total liabilities | $m | [30.3](/filings/0001410578-24-001704.md) | [25.9](/filings/0001410578-25-000329.md) | [29.0](/filings/0001410578-24-001706.md) | [15.6](/filings/0001410578-24-001708.md) | [20.7](/filings/0001410578-24-002012.md) | [9.8](/filings/0001104659-26-023167.md) | [6.4](/filings/0001410578-25-001205.md) | [6.2](/filings/0001410578-25-001778.md) | [5.2](/filings/0001104659-25-110827.md) | [5.1](/filings/0001104659-26-095426.md) | [6.4](/filings/0001104659-26-060678.md) | [6.8](/filings/0001104659-26-095426.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(28.0)](/filings/0001410578-24-002012.md) | [(15.2)](/filings/0001104659-26-023167.md) | [12.5](/filings/0001104659-25-110827.md) | [12.4](/filings/0001104659-25-110827.md) | [15.2](/filings/0001104659-25-110827.md) | [14.3](/filings/0001104659-26-095426.md) | [8.3](/filings/0001104659-26-095426.md) | [6.1](/filings/0001104659-26-095426.md) | [8.0](/filings/0001104659-25-110827.md) | [8.5](/filings/0001104659-26-095426.md) | [3.3](/filings/0001104659-26-095426.md) | [29.9](/filings/0001104659-26-095426.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.1) d](/filings/0001410578-24-002012.md) | [(9.6) d](/filings/0001410578-25-000329.md) | [(13.4)](/filings/0001410578-25-001205.md) | [(14.1) d](/filings/0001410578-25-001778.md) | [(9.2) d](/filings/0001104659-25-110827.md) | [(10.9) d](/filings/0001104659-26-023167.md) | [(9.4)](/filings/0001104659-26-060678.md) | [(5.1) d](/filings/0001104659-26-095426.md) | [(4.3) d](/filings/0001104659-25-110827.md) | [(4.3) d](/filings/0001104659-26-023167.md) | [(4.8)](/filings/0001104659-26-060678.md) | [(6.0) d](/filings/0001104659-26-095426.md) |
| Capital expenditure | $m | not reported | [0.3 d](/filings/0001410578-25-000329.md) | [0.0](/filings/0001410578-25-001205.md) | [0.0 d](/filings/0001410578-25-001778.md) | [0.0 d](/filings/0001104659-25-110827.md) | [0.1 d](/filings/0001104659-26-023167.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-060678.md) | [0.0 d](/filings/0001104659-26-095426.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.1](/filings/0001410578-24-001704.md) | [11.3](/filings/0001410578-24-001706.md) | [11.3](/filings/0001410578-24-001708.md) | [11.3](/filings/0001410578-24-002012.md) | [29.3](/filings/0001410578-25-001205.md) | [1.2](/filings/0001410578-25-001778.md) | [1.3](/filings/0001104659-25-110827.md) | [1.5](/filings/0001104659-26-060678.md) | [1.6](/filings/0001104659-26-095426.md) | [3.2](/filings/0001104659-25-110827.md) | [4.2](/filings/0001104659-26-060678.md) | [12.2](/filings/0001104659-26-095426.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,452,108 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095426.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.